<DOC>
	<DOCNO>NCT01727141</DOCNO>
	<brief_summary>This study ass efficacy , safety tolerability QVA149 patient moderate severe airflow limitation .</brief_summary>
	<brief_title>A 12 Week Treatment , Multi-center , Randomized , Double-blind , Parallel-group , Placebo Active Controlled Study Assess Efficacy , Safety , Tolerability Indacaterol Maleate / Glycopyrronium Bromide COPD Patients With Moderate Severe Airflow Limitation .</brief_title>
	<detailed_description>NOTE : Detailed Description : data enter</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Male female patient sign informed consent &gt; /= 40 year age . Patients stable COPD accord GOLD 2011 . Patients postbronchodilator FEV1 &gt; /= 30 % &lt; 80 % predict postbronchodilator FEV1/FVC &lt; 0.70 . Current exsmokers smoke history least 10 pack year . Patients mMRC grade 2 great . Patients Type I uncontrolled Type II diabetes Patients history long QT syndrome whose QTc measure Visit 101 ( Fridericia method ) prolong ( &gt; 450 m male female ) confirm central assessor . ( These patient rescreened . ) Patients clinically significant ECG abnormality Visit 101 Visit 102 . ( These patient rescreened . ) Patients history malignancy organ system , treat untreated , within last five year . Patients narrowangle glaucoma , BPH bladderneck obstruction moderatesevere renal impairment urinary retention . Patients COPD exacerbation within 6 week prior screen . Patients respiratory tract infection within 4 week prior screen . Patients require long term oxygen therapy prescribe 12 hr per day . Patients history asthma . 8 . Patients onset respiratory symptom , include COPD diagnosis , prior age 40 year . Patients blood eosinophil count great 600 mm/3 runin . Patients concomitant pulmonary disease . Patients diagnosis alpha1 antitrypsin deficiency . Patients active pulmonary tuberculosis . Patients active phase pulmonary rehabilitation programme . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>COPD , QVA149</keyword>
</DOC>